Does SUMATRIPTAN Cause Application site discolouration? 684 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 684 reports of Application site discolouration have been filed in association with SUMATRIPTAN (sumatriptan succinate). This represents 3.9% of all adverse event reports for SUMATRIPTAN.
684
Reports of Application site discolouration with SUMATRIPTAN
3.9%
of all SUMATRIPTAN reports
0
Deaths
2
Hospitalizations
How Dangerous Is Application site discolouration From SUMATRIPTAN?
Of the 684 reports, 2 (0.3%) required hospitalization.
Is Application site discolouration Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SUMATRIPTAN. However, 684 reports have been filed with the FAERS database.
What Other Side Effects Does SUMATRIPTAN Cause?
Drug ineffective (2,941)
Product physical issue (2,349)
Application site erythema (1,875)
Drug dose omission (1,711)
Product quality issue (1,269)
Application site pain (1,217)
Migraine (978)
Headache (914)
Product complaint (718)
Nausea (702)
What Other Drugs Cause Application site discolouration?
BUPRENORPHINE (208)
INGENOL MEBUTATE (115)
MECHLORETHAMINE (101)
ESTRADIOL (89)
NICOTINE (87)
MINOXIDIL (76)
SALICYLIC ACID (76)
BECAPLERMIN (74)
DICLOFENAC (67)
METHYLPHENIDATE (61)
Which SUMATRIPTAN Alternatives Have Lower Application site discolouration Risk?
SUMATRIPTAN vs SUMATRIPTAN\SUMATRIPTAN
SUMATRIPTAN vs SUMAVEL DOSEPRO
SUMATRIPTAN vs SUNITINIB
SUMATRIPTAN vs SUNITINIB MALATE
SUMATRIPTAN vs SUTENT